Cancer stem cells in head and neck cancer

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 375-383

  Allegra, Eugenia ^a   Trapasso, Serena ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cancer stem cells; Head and neck cancer; Tumor markers

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CD24 ANTIGEN; HERMES ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; BRAIN CANCER; CANCER RESEARCH; CANCER STEM CELL; CELL ISOLATION; CELL RENEWAL; COLORECTAL CANCER; EMBRYONIC STEM CELL; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; LUNG CANCER; METASTASIS; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SOLID TUMOR; TUMOR GROWTH;

EID: 84873423783     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S38694     Document Type: Review

References (104)

1. Garozzo A, Allegra E, La Boria A, Lombardo N. Modified supracricoid laryngectomy. Otolaryngol Head Neck Surg. 2010;142:137-139.
2. Allegra E, Lombardo N, La Boria A, et al. Quality of voice evaluation in patients treated by supracricoid laryngectomy and Modified supracricoid laryngectomy. Otolaryngol Head Neck Surg. 2011;145:789-795.
3. Allegra E, Franco T, Trapasso S, Aragona T, Domanico R, Garozzo A. Quality of life in patients treated by organ preservation surgery for early laryngeal carcinoma. Open Access Surg. 2012;5:27-32.
4. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46: 765-781.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
6. Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer. 1995;75:1343-1353.
7. Allegra E, Baudi F, La Boria A, Fagiani F, Garozzo A, Costanzo FS. Multiple head and neck tumours and their genetic relationship. Acta Otorhinolaryngol Ital. 2009;29:237-241.
8. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73:187-190.
9. Sjögren E V, Wiggenraad RG, Le Cessie S, Snijder S, Pomp J, Baatenburg de Jong RJ. Outcome of radiotherapy in T1 glottic carcinoma: a population-based study. Eur Arch Otorhinolaryngol. 2009;266:735-744.
10. Franchin G, Minatel E, Gobitti C, et al. Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients. Cancer. 2003;98: 765-772.
11. Durante F. Nesso fsio-patologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. [Nessus pathophysiological between the faw structure of the mother and the genesis of some malignant tumors]. Arch Memor Observ Chir Prat. 1874;11:217. Italian.
12. Cohnheim J. Congenitales, quergestreiftes muskelsarkon der nireren. [Congenitales, striated muscle sarkoma of the kidney]. Virchows Arch. 1875;65:64. Italian.
13. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14: 213-222.
14. Pierce GM, Dixon FJ, Verney E. Teratocarcinogenic and tissue forming potentials of the cell types comprising neoplastic embryoid bodies. Lab Invest. 1960;9:583-602.
15. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective Identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-3988.
18. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-5828.
19. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective Identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946-10951.
20. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104:10158-10163.
21. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-1037.
22. Ho MM, Ng AV, Lam S, Hung J Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4827-4833.
23. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104: 973-978.
24. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
25. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504-514.
26. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-323.
27. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopula-tion with stem cell properties in melanomas. Cancer Res. 2005;65: 9328-9337.
28. Costea DE, Tsinkalovsky O, Vintermyr OK, Johannessen AC, Mackenzie IC. Cancer stem cells - new and potentially important targets for the therapy of oral squamous cell carcinoma. Oral Dis. 2006;12:443-454.
29. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23-28.
30. Califano J, Westra WH, Meininger G, Corio R, Koch WM, Sidransky D. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res. 2000;2:347-352.
31. Garozzo A, Cutrona D, Palmeri S, Maiolino L, Puzzo L, Allegra E. The role of p53 tumor suppressor gene as prognostic factor in laryn-geal squamous cell carcinoma. Acta Otorhinolaryngol Ital. 1999;19: 342-347. Italian.
32. Allegra E, Garozzo A, Lombardo N, De Clemente M, Carey TE. Mutations and polymorphisms in mitochondrial DNA in head and neck cancer cell lines. Acta Otorhinolaryngol Ital. 2006;26:185-190.
33. Scadden DT. The stem-cell niche as an entity of action. Nature. 2006;441:1075-1079.
34. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol. 2005;21:605-631.
35. Scadden DT. The stem-cell niche as an entity of action. Nature. 2006;441:1075-1079.
36. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133: 704-715.
37. Morel A P, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008;3:e2888.
38. Radisky DC, LaBarge MA. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell. 2008;2:511-512.
39. Thiery J P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
40. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010;101:293-299.
41. Albers AE, Chen C, Köberle B, et al. Stem cells in squamous head and neck cancer. Crit Rev Oncol Hematol. 2012;81:224-240.
42. Chen C, Wei Y, Hummel M, et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One. 2011;6:e16466.
43. Bauer N, Fonseca AV, Florek M, et al. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs. 2008;188:127-138.
44. Shmelkov S V, St Clair R, Lyden D, Rafi S. AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 2005;37:715-719.
45. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-110.
46. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18:1127-1134.
47. Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD. A subpopulation of CD133+ cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett. 2010;289:151-160.
48. Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ, Maccallum J. In vivo investigation of CD133 as a putative marker of cancer stem cells in hep-2 cell line. Head Neck. 2009;31:94-101.
49. Zhou L, Wei X, Cheng L, Tian J, Jiang JJ. CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope. 2007;117: 455-460.
50. Isacke CM, Yarwood H. The hyaluronan receptor, CD44. Int J Biochem Cell Biol. 2002;34:718-721.
51. Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metallo-proteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001;153:893-904.
52. Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract. 2005;201:479-486.
53. Bosron W F, Lumeng L, Li TK. Genetic polymorphism of enzymes of alcohol metabolism and susceptibility to alcoholic liver disease. Mol Aspects Med. 1988;10:147-158.
54. Thomasson HR, Edenberg HJ, Crabb DW, et al. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. Am J Hum Genet. 1991;48:677-681.
55. Visus C, Ito D, Amoscato A, et al. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 2007;67:10538-10545.
56. Clay MR, Tabor M, Owen JH, et al. Single-marker Identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32:1195-1201.
57. Zhang P, Zhang Y, Mao L, Zhang Z, Chen W. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett. 2009;277:227-234.
58. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug effux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004;101:14228-14233.
59. Loebinger MR, Giangreco A, Groot KR, et al. Squamous cell cancers contain a side population of stem-like cells that are made chemosensi-tive by ABC transporter blockade. Br J Cancer. 2008;98:380-387.
60. Tabor MH, Clay MR, Owen JH, et al. Head and neck cancer stem cells: the side population. Laryngoscope. 2011;121:527-533.
61. Okamoto A, Chikamatsu K, Sakakura K, Hatsushika K, Takahashi G, Masuyama K. Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol. 2009;45:633-639.
62. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008;14:4085-4095.
63. Lim YC, Oh SY, Cha YY, Kim SH, Jin X, Kim H. Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral Oncol. 2011;47:83-91.
64. Trapasso S, Allegra E. Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biologics. 2012;6:379-383.
65. van Hal NL, van Dongen GA, Stigter-van Walsum M, Snow GB, Brak-enhoff RH. Characterization of CD44v6 isoforms in head and neck squamous cell carcinoma. Int J Cancer. 1999;82:837-845.
66. Mack B, Gires O. CD44s and CD44v6 expression in head and neck epithelia. PLoS One. 2008;3:e3360.
67. Herold-Mende C, Seiter S, Born AI, et al. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. J Pathol. 1996;179:66-73.
68. Kanke M, Fujuu M, Kameyama K, et al. Role of CD44 variant exon 6 in invasion of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2000;126:1217-1223.
69. Joshua B, Kaplan MJ, Doweck I, et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck. 2012;34:42-49.
70. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope. 2009;119:1518-1530.
71. Koukourakis MI, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E. Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer. 2012;106:846-853.
72. Bahar R, Kunishi M, Kayada Y, Yoshiga K. CD44 variant 6 (CD44v6) expression as a progression marker in benign, premalignant and malignant oral epithelial tissues. Int J Oral Maxillofac Surg. 1997;26:443-446.
73. Ue T, Yokozaki H, Kagai K, et al. Reduced expression of the CD44 variant exons in oral squamous cell carcinoma and its relationship to metastasis. J Oral Pathol Med. 1998;27:197-201.
74. Oliveira LR, Oliveira-Costa J P, Araujo IM, et al. Cancer stem cell immunophenotypes in oral squamous cell carcinoma. J Oral Pathol Med. 2011;40:135-142.
75. Stoll C, Baretton G, Soost F, Löhrs U. The influence of CD44 splice variants to the outcome of patients with oral squamous cell carcinoma. Adv Exp Med Biol. 1998;451:51-55.
76. Uwa N, Kataoka TR, Torii I, et al. CD44 expression is related to poor prognosis of hypopharyngeal squamous cell carcinoma. Acta Otolar-yngol. 2011;131:323-329.
77. Carinci F, Stabellini G, Calvitti M, et al. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg. 2002;13:85-89.
78. Kokko LL, Hurme S, Maula SM, et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 2011;47:510-516.
79. Bloor BK, Rajarajan A, Jaafary-Haghighat K, Odell E W. Transcription and expression of CD44 variant exons by oro-pharyngeal squamous cell carcinomas. Int J Oncol. 2002;21:907-913.
80. Lindquist D, Ahrlund-Richter A, Tarján M, Tot T, Dalianis T. Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res. 2012;32:153-161.
81. Fonseca I, Pereira T, Rosa-Santos J, Soares J. Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: a correlation with histological grade, pattern of stromal invasion, and cell differentiation. J Surg Oncol. 2001;76:115-120.
82. Mostaan LV, Khorsandi MT, Sharifan SM, et al. Correlation between E-cadherin and CD44 adhesion molecules expression and cervical lymph node metastasis in oral tongue SCC: predictive significance or not. Pathol Res Pract. 2011;207:448-451.
83. Rodrigo J P, Domínguez F, Alvarez C, González M V, Herrero A, Suárez C. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. Am J Clin Pathol. 2002;118:67-72.
84. Masuda M, Kuratomi Y, Shiratsuchi H, Nakashima T, Naonobu K, Komiyama S. Decreased CD44H expression in early-stage tongue carcinoma associates with late nodal metastases following interstitial brachytherapy. Head Neck. 2000;22:662-665.
85. Yüce I, Bayram A, Caǧli S, Canöz O, Bayram S, Güney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol. 2011;32:141-146.
86. Sun B, Zhao S, Zhou C, Yan Q, Wang H. Detection of PD4, CD44, PCNA protein and its clinical significance in human laryngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010;24:817-819. Chinese.
87. Liu B, Kong W, Gong S, Yang C, Wang G, Zhu L. Relationship between the expression of CD44v6 and development, progress, invasion and metastasis of laryngeal carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2005;25:351-353, 364.
88. Zhao S, Sun B, He J, Ye Q, Lin S, Sun A. The expression of CD44 and its significance in human laryngeal carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2003;17:164-166. Chinese.
89. de Jong MC, Pramana J, van der Wal JE, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res. 2010;16:5329-5338.
90. Yang X, Liu M, Han E, Guo H, Yang Z. Expression and implication of CD44 and nm23-H1 proteins in laryngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;22:119-122. Chinese.
91. Lu S, Tian J, Lv Z, et al. The probable role of tumor stem cells for lymph node metastasis in supraglottic carcinoma. Pathol Oncol Res. 2011;17:33-38.
92. Staibano S, Merolla F, Testa D, et al. OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. Br J Cancer. 2007;97:1545-1551.
93. Rodrigo J P, Dominguez F, Alvarez C, Herrero A, Suarez C. Expression of E-cadherin, CD44s, and CD44v6 in laryngeal and pharyngeal carcinomas. Am J Otolaryngol. 2003;24:384-389.
94. Ostwald J, Pracht O, Rhode E, Kramp B. Are the products of CD44 exons v5 and v6 markers for metastasis of laryngeal carcinomas? Laryngorhinootologie. 1997;76:295-299. German.
95. Woinska-Rojecka T, Chodynicki S, Chyczewski L, Rzewnicki I. CD44 glycoprotein as a prognostic factor in laryngeal cancer. Folia Histochem Cytobiol. 2001;39 Suppl 2:150-151.
96. Franzmann EJ, Reategui E P, Pereira LH, et al. Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck. 2012;34: 687-695.
97. Franzmann EJ, Reategui E P, Pedroso F, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1348-1355.
98. Franzmann EJ, Reategui E P, Carraway KL, Hamilton KL, Weed DT, Goodwin WJ. Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2005;14: 735-739.
99. Allegra E, Trapasso S, Sacco A, Aragona T, Belfore A, Garozzo A. CD44sol salivary levels detected by ELISA as a diagnostic test for laryngeal carcinomas. J Cancer Sci Ther. 2012;4:330-334.
100. Xu J, Müller S, Nannapaneni S, et al. Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. Eur J Cancer. 2012;48:1682-1691.
101. Yu CC, Lo WL, Chen Y W, et al. Bmi-1 regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1-positive cells. J Oncol. 2011;2011:1-16.
102. Chen YC, Chang CJ, Hsu HS, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol. 2010;46:158-165.
103. Allegra E, Puzzo L, Zuccalà V, et al. Nuclear BMI-1 expression in laryngeal carcinoma correlates with lymph node pathological status. World J Surg Oncol. 2012;10:206.
104. Allegra E, Caltabiano R, Amorosi A, Vasquez E, Garozzo A, Puzzo L. Expression of BMI1 and p16 in laryngeal squamous cell carcinoma. Head Neck. Epub June 22, 2012.